ClinicalTrials.gg
CompletedNCT02241772Updated Feb 16, 2015

A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)

A Phase 1/2 interventional study of TA-8995 and Placebo in Elevated Lp(a), sponsored by Xention Ltd. Completed at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-16.

Sponsored by Xention Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A study in males and females with elevated Lp(a) to look at the effects of TA-8995 on Lp(a) levels.

02

Conditions studied

  • Elevated Lp(a)
03

In context

Lead sponsor

Xention Ltd is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female (of non-child bearing potential) subjects with elevated Lp(a) levels

Exclusion criteria

Exclusion Criteria:

  • medical history
  • Abnormal laboratory results (other than lipid levels) or vital signs
  • Receiving any other drug therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    10mg TA-8995

    10mg TA-8995 once daily

    Drug: TA-8995

  • Experimental
    2.5mg TA-8995

    2.5mg TA-8995 once daily

    Drug: TA-8995

  • Placebo comparator
    Placebo to TA-8995

    Placebo to TA-8995 once daily.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the change from baseline in (Lp(a) levels after 12 weeks of treatment with TA-8995.

    Time frame: 12 weeks

Secondary outcomes

  1. Number of participants with adverse events

    Time frame: 12 weeks

07

Study locations

1 site
  • Herlev Hospital
    Herlev, DK-2730, Denmark
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Jan 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2014
First posted
Sep 16, 2014
Start
Sep 2014
Primary completionActual
Jan 2015
CompletionActual
Feb 2015
Last update
Feb 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02241772
Lead sponsor
Xention Ltd
Responsible party
Sponsor
First posted
Sep 16, 2014
Start date
Sep 2014
Primary completion
Jan 2015
Completion
Feb 2015
Last update
Feb 16, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TA-8995

Start the discussion